person · Reporting owner

MATLIN DAVID J

Disclosed activity across 7 companies

Tapewire entity: 23297
SEC CIK: 0001251956

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CalAtlantic Group, Inc.CAA · Entity 169490	10% owner	June 14, 2017	June 15, 2017
Clene Inc.CLNN · Entity 7166	Director	September 16, 2026	September 18, 2026
FLAGSTAR BANCORP INC(NYSE:FBC) · Entity 121881	Director	January 20, 2021	January 21, 2021
MedAvail Holdings, Inc.MYOS · Entity 94590	10% owner	March 06, 2020	March 10, 2020
TriSalus Life Sciences, Inc.TLSI · Entity 5872	Director	May 14, 2026	May 15, 2026
U.S. WELL SERVICES HOLDINGS, LLCUSWS · Entity 122531	Director	March 02, 2022	March 04, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CalAtlantic Group, Inc.

Report date June 14, 2017 · Filed June 15, 2017

Jointly reported with MP CA Homes LLC, MatlinPatterson Global Opportunities Partners III LP, MatlinPatterson Global Opportunities Partners (Cayman) III LP, MatlinPatterson Global Partners III LLC, MATLINPATTERSON GLOBAL ADVISERS LLC, MatlinPatterson PE Holdings LLC, MATLINPATTERSON LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,332,549	Reported balance After 2017-06-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-06-14 · Sale · Disposed 14,510,008 · Balance 28,332,549 F1: MP CA Homes LLC was the direct owner of 42,842,557 shares of Common Stock. On June 14, 2017, MP CA Homes LLC sold 11,500,000 shares of Common Stock in an underwritten public offering and 3,010,008 shares of Common Stock to the Issuer in a direct share repurchase. MatlinPatterson Global Opportunities Partners III L.P. and MatlinPatterson Global Opportunities Partners (Cayman) III L.P. (together, "the Funds"), hold 100 percent of the membership interests in MP CA Homes LLC. MatlinPatterson Global Partners III LLC (the "General Partner") is the general partner of the Funds. MatlinPatterson Global Advisers LLC (the "Adviser") is the investment adviser to the Funds. MatlinPatterson PE Holdings LLC holds 100 percent of the voting interest and equity of the Adviser and the General Partner. (Continued in footnote 2) F2: MatlinPatterson LLC holds 100 percent of the equity of MatlinPatterson PE Holdings LLC. Other than MP CA Homes LLC, each of the foregoing reporting persons disclaims beneficial ownership of the shares held by MP CA Homes LLC, except to the extent that such reporting person holds an indirect pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3: David J. Matlin is an employee of the Adviser and a holder of 100 percent of the membership interests in MatlinPatterson LLC. He also has an indirect pecuniary interest in the Funds. His exact pecuniary interest therein is not readily determinable because it is subject to several variables, including without limitation, the internal rates of return of the Funds overall with respect to their indirect investment in the Issuer. David J. Matlin disclaims beneficial ownership of any of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: MP CA Homes LLC was the direct owner of 42,842,557 shares of Common Stock. On June 14, 2017, MP CA Homes LLC sold 11,500,000 shares of Common Stock in an underwritten public offering and 3,010,008 shares of Common Stock to the Issuer in a direct share repurchase. MatlinPatterson Global Opportunities Partners III L.P. and MatlinPatterson Global Opportunities Partners (Cayman) III L.P. (together, "the Funds"), hold 100 percent of the membership interests in MP CA Homes LLC. MatlinPatterson Global Partners III LLC (the "General Partner") is the general partner of the Funds. MatlinPatterson Global Advisers LLC (the "Adviser") is the investment adviser to the Funds. MatlinPatterson PE Holdings LLC holds 100 percent of the voting interest and equity of the Adviser and the General Partner. (Continued in footnote 2)

F2: MatlinPatterson LLC holds 100 percent of the equity of MatlinPatterson PE Holdings LLC. Other than MP CA Homes LLC, each of the foregoing reporting persons disclaims beneficial ownership of the shares held by MP CA Homes LLC, except to the extent that such reporting person holds an indirect pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: David J. Matlin is an employee of the Adviser and a holder of 100 percent of the membership interests in MatlinPatterson LLC. He also has an indirect pecuniary interest in the Funds. His exact pecuniary interest therein is not readily determinable because it is subject to several variables, including without limitation, the internal rates of return of the Funds overall with respect to their indirect investment in the Issuer. David J. Matlin disclaims beneficial ownership of any of the reported securities except to the extent of his pecuniary interest therein.

Clene Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
common stockSEC Table I · non-derivative	Direct	912,275	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Grant · Acquired 434,451 · Balance 912,275 F1: Mr. Matlin purchased 434,451 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.
common stockSEC Table I · non-derivative	IndirectBy trust	7,500	Reported balance Holding disclosure · report date 2026-09-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,500 F2: The securities are owned by the Matlin Family Trust 2020. Mr. Matlin is the trustee of the Matlin Family Trust 2020. The shares owned by the Matlin Family Trust 2020 may be beneficially owned by Mr. Matlin.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Matlin purchased 434,451 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.

F2: The securities are owned by the Matlin Family Trust 2020. Mr. Matlin is the trustee of the Matlin Family Trust 2020. The shares owned by the Matlin Family Trust 2020 may be beneficially owned by Mr. Matlin.

FLAGSTAR BANCORP INC

Report date January 20, 2021 · Filed January 21, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Flagstar Bancorp, Inc. Common StockSEC Table I · non-derivative	Direct	2,867	Reported balance After 2021-01-20 transaction · row 1 1 source row Row 1 · 2021-01-20 · Grant · Acquired 2,426 · Balance 2,867

MedAvail Holdings, Inc.

Report date March 06, 2020 · Filed March 10, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,267,477	Reported balance After 2020-03-06 transaction · row 1 1 source row Row 1 · 2020-03-06 · Purchase · Acquired 206,611 · Balance 1,267,477

TriSalus Life Sciences, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,323,210	Ending reported balance After 2026-05-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-14 · Grant · Acquired 28,201 · Balance 1,300,145 F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2026-05-14 · Grant · Acquired 23,065 · Balance 1,323,210 F2: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2036-05-13	Direct	121,403	Reported balance After 2026-05-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-14 · Grant · Acquired 56,403 · Balance 121,403 F3: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

F2: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.

F3: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

U.S. WELL SERVICES HOLDINGS, LLC

Report date March 02, 2022 · Filed March 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Warrants (right to buy)SEC Table II · derivative / convertible security	Direct	697,674	Reported balance After 2022-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-03-02 · Grant · Acquired 697,674 · Balance 697,674 F1: Reflects the issuance by the Issuer of 697,674 warrants ("Warrants") exercisable for shares of Class A common stock of the Issuer, par value $0.0001 per share ("Class A Common Stock"), to the Reporting Person on March 2, 2022 in connection with the entry into that certain Joinder to Senior Secured Term Loan Agreement dated March 1, 2022 (the "Joinder to Credit Agreement") and the extension of a $1.5 million term loan to a subsidiary of the Issuer, and pursuant to the applicable Warrant Agreement (the "Warrant Agreement"). F2: In accordance with the Warrant Agreement, the exercise price of the Warrants is $1.29 per share, subject to adjustment for stock splits, combinations, certain distributions or similar events in accordance with the terms of the Warrant Agreement. All or any portion of the Warrants issued pursuant to the Warrant Agreement may be exercised by the Reporting Person at any time prior to expiration in accordance with the terms of the Warrant Agreement. The Warrants expire on March 1, 2028. F3: Upon exercise by the Reporting Person, pursuant to the Warrant Agreement, the Warrants are required to be net settled in shares of Class A Common Stock, on a cashless basis based on the difference between (i) the volume weighted average price of Class A Common Stock as reported during the ten trading day period ending on the second trading day prior to the date on which the notice of exercise is delivered to the warrant agent and (ii) the then-applicable exercise price, in each case, at the time of exercise. F4: As a result, the number of shares of Class A Common Stock issuable upon exercise of the Warrants cannot be determined at this time; however, in no event will the Warrants be exercisable for more than 697,674 shares of Class A Common Stock (subject to adjustment for stock splits, combinations, certain distributions or similar events).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the issuance by the Issuer of 697,674 warrants ("Warrants") exercisable for shares of Class A common stock of the Issuer, par value $0.0001 per share ("Class A Common Stock"), to the Reporting Person on March 2, 2022 in connection with the entry into that certain Joinder to Senior Secured Term Loan Agreement dated March 1, 2022 (the "Joinder to Credit Agreement") and the extension of a $1.5 million term loan to a subsidiary of the Issuer, and pursuant to the applicable Warrant Agreement (the "Warrant Agreement").

F2: In accordance with the Warrant Agreement, the exercise price of the Warrants is $1.29 per share, subject to adjustment for stock splits, combinations, certain distributions or similar events in accordance with the terms of the Warrant Agreement. All or any portion of the Warrants issued pursuant to the Warrant Agreement may be exercised by the Reporting Person at any time prior to expiration in accordance with the terms of the Warrant Agreement. The Warrants expire on March 1, 2028.

F3: Upon exercise by the Reporting Person, pursuant to the Warrant Agreement, the Warrants are required to be net settled in shares of Class A Common Stock, on a cashless basis based on the difference between (i) the volume weighted average price of Class A Common Stock as reported during the ten trading day period ending on the second trading day prior to the date on which the notice of exercise is delivered to the warrant agent and (ii) the then-applicable exercise price, in each case, at the time of exercise.

F4: As a result, the number of shares of Class A Common Stock issuable upon exercise of the Warrants cannot be determined at this time; however, in no event will the Warrants be exercisable for more than 697,674 shares of Class A Common Stock (subject to adjustment for stock splits, combinations, certain distributions or similar events).

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Lonestar Resources US Inc.

Report date October 05, 2021 · Filed October 21, 2021

Section 16 reporting ended · disclosed 2021-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-10-05 transaction · row 1 1 source row Row 1 · 2021-10-05 · Disposition to issuer · Disposed 1,909,786 · Balance 0 F1: On October 5, 2021, pursuant to the Agreement and Plan of Merger dated as of July 10, 2021 (the "Merger Agreement"), by and among Penn Virginia Corporation ("Penn Virginia"), Lonestar Resources US Inc. ("Lonestar") and the other parties thereto, Upsilon Merger Sub Inc. merged with and into Lonestar (the "First Merger"), with Lonestar surviving the First Merger as the surviving corporation (the "Surviving Corporation"), and, following the First Merger, the Surviving Corporation merged with and into Pi Merger Sub LLC ("Merger Sub LLC"), with Merger Sub LLC continuing as the surviving entity. Pursuant to the Merger Agreement, each share of Lonestar common stock issued and outstanding immediately prior to the effective time of the First Merger was converted into the right to receive 0.51 shares of Penn Virginia common stock. F2: On October 4, 2021 (the day prior to the effective time of the First Merger), the closing price of one share of Penn Virginia common stock was $32.32.

Filing footnotes · ownership attribution and instrument terms

F1: On October 5, 2021, pursuant to the Agreement and Plan of Merger dated as of July 10, 2021 (the "Merger Agreement"), by and among Penn Virginia Corporation ("Penn Virginia"), Lonestar Resources US Inc. ("Lonestar") and the other parties thereto, Upsilon Merger Sub Inc. merged with and into Lonestar (the "First Merger"), with Lonestar surviving the First Merger as the surviving corporation (the "Surviving Corporation"), and, following the First Merger, the Surviving Corporation merged with and into Pi Merger Sub LLC ("Merger Sub LLC"), with Merger Sub LLC continuing as the surviving entity. Pursuant to the Merger Agreement, each share of Lonestar common stock issued and outstanding immediately prior to the effective time of the First Merger was converted into the right to receive 0.51 shares of Penn Virginia common stock.

F2: On October 4, 2021 (the day prior to the effective time of the First Merger), the closing price of one share of Penn Virginia common stock was $32.32.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2026 Filed Sep 18, 2026 17:42 UTC	Clene Inc. CLNN · Entity 7166	Grantcommon stock	434,451	$3.28	$1,424,999.28	Disclosure SEC source: 0001437749-26-030730 · rdgdoc.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,275 F1 · ownership.direct: Mr. Matlin purchased 434,451 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document
August 13, 2026 Filed Aug 14, 2026 19:30 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	6,230	$0.00 Strike: $4.19	$0.00	Disclosure SEC source: 0001437749-26-027968 · rdgdoc.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,230 Underlying: common stock · 6,230 shares Expires 2036-08-12 F1 · derivative.exercise_date: This option was granted on August 13, 2026 as an option for 6,230 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant. Read SEC document
May 21, 2026 Filed May 22, 2026 17:58 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	3,659	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001437749-26-018218 · rdgdoc.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,659 Underlying: common stock · 3,659 shares Expires 2036-05-20 F2 · derivative.exercise_date: This option was granted on May 21, 2026 as an option for 3,659 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant. Read SEC document
May 21, 2026 Filed May 22, 2026 17:58 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	1,500	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001437749-26-018218 · rdgdoc.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: common stock · 1,500 shares Expires 2036-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested. Read SEC document
May 14, 2026 Filed May 15, 2026 20:39 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantDirector Stock Option (right to buy) · Derivative	56,403	$0.00 Strike: $2.52	$0.00	Disclosure SEC source: 0001628280-26-035664 · wk-form4_1778877552.xml · derivative · entry 3 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,403 Underlying: Common Stock · 56,403 shares Expires 2036-05-13 F3 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 14, 2026 Filed May 15, 2026 20:39 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantCommon Stock	23,065	$0.00	$0.00	Disclosure SEC source: 0001628280-26-035664 · wk-form4_1778877552.xml · nonDerivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323,210 F2 · shares: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 14, 2026 Filed May 15, 2026 20:39 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantCommon Stock	28,201	$0.00	$0.00	Disclosure SEC source: 0001628280-26-035664 · wk-form4_1778877552.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,145 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document
February 19, 2026 Filed Feb 20, 2026 21:04 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	5,372	$0.00 Strike: $4.73	$0.00	Disclosure SEC source: 0001437749-26-004906 · rdgdoc.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,372 Underlying: common stock · 5,372 shares Expires 2036-02-18 F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 5,372 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant. Read SEC document
January 13, 2026 Filed Jan 13, 2026 19:48 UTC	Clene Inc. CLNN · Entity 7166	GrantWarrant (right to buy) · Derivative	93,333	Not disclosed Strike: $6.00	Not disclosed	Disclosure SEC source: 0001437749-26-001170 · rdgdoc.xml · derivative · entry 3 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,333 Underlying: common stock · Not disclosed shares Expires 2031-01-13 F5 · derivative.exercise_price: The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date. F6 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price. F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant. F6 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price. Read SEC document
January 13, 2026 Filed Jan 13, 2026 19:48 UTC	Clene Inc. CLNN · Entity 7166	GrantWarrant (right to buy) · Derivative	40,000	Not disclosed Strike: $6.00	Not disclosed	Disclosure SEC source: 0001437749-26-001170 · rdgdoc.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: common stock · Not disclosed shares Expires 2029-01-13 F3 · derivative.exercise_price: The exercise price of each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drug User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement "); or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement. F4 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price. F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant. F4 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price. Read SEC document
January 13, 2026 Filed Jan 13, 2026 19:48 UTC	Clene Inc. CLNN · Entity 7166	Purchasecommon stock	33,333	$6.50	$216,664.50	Disclosure SEC source: 0001437749-26-001170 · rdgdoc.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,824 F1 · date: The reporting person entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 33,333 shares of the Company's common stock, Series A Warrants to purchase 40,000 shares of the Company's common stock and Series B Warrants to purchase 93,333 shares of the Company's common stock, closing effective January 13, 2026. F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant. Read SEC document
November 13, 2025 Filed Nov 14, 2025 21:45 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	3,692	$0.00 Strike: $7.30	$0.00	Disclosure SEC source: 0001437749-25-035226 · rdgdoc.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,692 Underlying: common stock · 3,692 shares Expires 2035-11-12 F1 · derivative.exercise_date: This option was granted on November 13, 2025 as an option for 3,692 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $7.30 per share. The options vest immediately upon grant. Read SEC document
August 14, 2025 Filed Aug 15, 2025 13:12 UTC	Clene Inc. CLNN · Entity 7166	Grantstock option · Derivative	7,255	$0.00 Strike: $3.60	$0.00	Disclosure SEC source: 0001437749-25-027074 · rdgdoc.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,255 Underlying: common stock · 7,255 shares Expires 2035-08-13 F1 · derivative.exercise_date: This option was granted on August 14, 2025 as an option for 7,255 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The options vest immediately upon grant. Read SEC document
July 31, 2025 Filed Apr 1, 2026 20:09 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	ConversionSeries A Preferred Stock · Derivative	100,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001628280-26-022792 · wk-form4_1775074153.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 330,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share. F3 · shares: On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer. F3 · derivative.exercise_date: On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer. F3 · derivative.expiration_date: On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer. F3 · derivative.underlying_shares: On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer. F3 · balance_after: On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer. Read SEC document
July 31, 2025 Filed Apr 1, 2026 20:09 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	ConversionCommon Stock	330,000	$0.00	$0.00	Disclosure SEC source: 0001628280-26-022792 · wk-form4_1775074153.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,271,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II. Read SEC document
June 12, 2025 Filed Jun 27, 2025 20:20 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantDirector Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $5.50	$0.00	Disclosure SEC source: 0001826667-25-000085 · wk-form4_1751055648.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document
May 22, 2025 Filed May 23, 2025 18:58 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	1,500	$0.00 Strike: $2.45	$0.00	Disclosure SEC source: 0001562180-25-004126 · primarydocument.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-05-21 F2 · derivative.exercise_date: This option was granted on May 22, 2025 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $2.45 per share. The options vest in 12 equal monthly installments on the 22nd day of each calendar month, beginning June 22, 2025, until such shares are fully vested. Read SEC document
May 22, 2025 Filed May 23, 2025 18:58 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	10,209	$0.00 Strike: $2.45	$0.00	Disclosure SEC source: 0001562180-25-004126 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,209 Underlying: Common Stock · 10,209 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2025 as an option for 10,209 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $2.45 per share. The options vest immediately upon grant. Read SEC document
February 27, 2025 Filed Feb 28, 2025 21:22 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	5,628	$0.00 Strike: $4.42	$0.00	Disclosure SEC source: 0001562180-25-001809 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,628 Underlying: Common Stock · 5,628 shares Expires 2035-02-26 F1 · derivative.exercise_date: This option was granted on February 27, 2025 as an option for 5,628 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.42 per share. The options vest immediately upon grant. Read SEC document
February 10, 2025 Filed Feb 11, 2025 23:04 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	OtherSeries A Preferred Stock · Derivative	89,501	$0.00 Strike: $5.28	$0.00	Disclosure SEC source: 0001415889-25-003623 · form4-02112025_110217.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,501 Underlying: Common Stock · 89,501 shares Expires not disclosed F1 · derivative.exercise_price: The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023. F2 · kind: Effective February 10, 2025, the Conversion Price of the 100,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F2 · shares: Effective February 10, 2025, the Conversion Price of the 100,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F3 · derivative.exercise_date: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 189,501 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. F4 · derivative.expiration_date: All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. F5 · derivative.underlying_shares: Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset. F3 · balance_after: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 189,501 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. Read SEC document
January 02, 2025 Filed Jan 6, 2025 22:57 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantCommon Stock	10,040	$0.00	$0.00	Disclosure SEC source: 0001415889-25-000830 · form4-01062025_100110.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 941,944 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the RSU Award in lieu of the 2025 cash Annual Board Service Retainer provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the RSU Award shall vest in equal quarterly installments on each of March 31, June 30, September 30 and December 31, 2025, subject to the Reporting Person's continued service with the Issuer. Read SEC document
December 06, 2024 Filed Dec 9, 2024 21:17 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	5,563	$0.00 Strike: $4.40	$0.00	Disclosure SEC source: 0001562180-24-008238 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,563 Underlying: Common Stock · 5,563 shares Expires 2034-12-05 F1 · derivative.exercise_date: This option was granted on December 6, 2024 as an option for 5,563 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.40 per share. The options vest immediately upon grant. Read SEC document
October 02, 2024 Filed Oct 3, 2024 20:12 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	4,990	$0.00 Strike: $4.89	$0.00	Disclosure SEC source: 0001562180-24-007210 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,990 Underlying: Common Stock · 4,990 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option was granted on October 2, 2024 as an option for 4,990 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.89 per share. The options vest immediately upon grant. Read SEC document
September 30, 2024 Filed Oct 2, 2024 16:58 UTC	Clene Inc. CLNN · Entity 7166	GrantWarrants (Right to buy) · Derivative	92,307	$0.13 Strike: $4.82	$11,538.38	Disclosure SEC source: 0001562180-24-007098 · primarydocument.xml · derivative · entry 3 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,307 Underlying: Common Stock · 92,307 shares Expires 2029-10-01 Read SEC document
September 30, 2024 Filed Oct 2, 2024 16:58 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	92,307	$4.75	$438,458.25	Disclosure SEC source: 0001562180-24-007098 · primarydocument.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,491 F1 · balance_after: On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's previously owned 7,043,686 shares of common stock being reduced to 352,184 shares of common stock. Read SEC document
August 13, 2024 Filed Aug 22, 2024 00:40 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantDirector stock option (right to buy) · Derivative	15,000	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0001415889-24-021946 · form4-08222024_120854.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document
June 07, 2024 Filed Jun 10, 2024 20:18 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	65,723	$0.00 Strike: $0.37	$0.00	Disclosure SEC source: 0001562180-24-004903 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,723 Underlying: Common Stock · 65,723 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 65,723 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest immediately upon grant. Read SEC document
May 29, 2024 Filed May 31, 2024 18:23 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	30,000	$0.00 Strike: $30,000.00	$0.00	Disclosure SEC source: 0001562180-24-004534 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option was granted on May 29, 2024 as an option for 30,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest in 12 equal installments of Common Stock on the 29th day of each calendar month, beginning June 29, 2024, until such shares are fully vested. Read SEC document
March 11, 2024 Filed Mar 12, 2024 20:20 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	57,488	$0.00 Strike: $0.44	$0.00	Disclosure SEC source: 0001562180-24-002594 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,488 Underlying: Common Stock · 57,488 shares Expires 2034-03-11 F1 · derivative.exercise_date: This option was granted on March 11, 2024 as an option for 57,488 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.44 per share. The options vest immediately upon grant. Read SEC document
November 28, 2023 Filed Nov 29, 2023 21:09 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	56,024	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-23-007968 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,024 Underlying: Common Stock · 56,024 shares Expires 2033-11-28 F1 · derivative.exercise_date: This option was granted on November 28, 2023 as an option for 56,024 shares of Common Stock under the Clene Inc. 2020 Amended Stock Plan at an exercise price of $0.45 per share. The options vest immediately upon grant. Read SEC document
November 10, 2023 Filed Nov 13, 2023 12:48 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	250,002	$0.41	$102,500.82	Disclosure SEC source: 0001562180-23-007625 · primarydocument.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,043,686 F1 · price: Mr. Matlin purchased 250,002 shares of common stock of Clene Inc. on November 10, 2023 at prices ranging from $0.39 to $0.42, inclusive, for a weighted average price of $0.40. Read SEC document
September 18, 2023 Filed Sep 19, 2023 20:07 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	46,659	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001562180-23-006935 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,659 Underlying: Common Stock · 46,659 shares Expires 2033-09-18 F1 · derivative.exercise_date: This option was granted on September 18, 2023 as an option for 46,659 shares of Common Stock under the Clene Inc. 2020 Amended Stock Plan at an exercise price of $0.54 per share. The options vest immediately upon grant. Read SEC document
August 10, 2023 Filed Aug 14, 2023 21:58 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantSeries A Preferred Stock · Derivative	100,000	$10.00 Strike: $10.00	$1,000,000.00	Disclosure SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 4 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F5 · derivative.exercise_date: The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. F5 · derivative.expiration_date: The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. Read SEC document
August 10, 2023 Filed Aug 14, 2023 21:58 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $11.34	$0.00	Disclosure SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 3 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2023-08-08 F4 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document
August 10, 2023 Filed Aug 14, 2023 21:58 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	OtherRedeemable Warrants · Derivative	1,240,518	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,240,518 Underlying: Common Stock · 1,240,518 shares Expires not disclosed F2 · kind: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement. F2 · price: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement. F3 · derivative.expiration_date: The redeemable warrants expire on August 10, 2028, or earlier upon redemption or liquidation. F2 · balance_after: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement. Read SEC document
August 10, 2023 Filed Aug 14, 2023 21:58 UTC	TriSalus Life Sciences, Inc. TLSI · Entity 5872	OtherCommon Stock	931,904	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045693 · doc4.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931,904 F1 · kind: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member. F1 · price: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member. F1 · balance_after: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member. Read SEC document
June 26, 2023 Filed Jun 27, 2023 20:13 UTC	TriSalus Life Sciences, Inc. MTAC · Entity 5872	ConversionClass B Common Stock · Derivative	6,249,999	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · derivative · entry 2 MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner Dewey Christopher C · CIK 0001385015 · 10% owner MATLIN DAVID J · CIK 0001251956 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 Underlying: Class A Common Stock · 6,249,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · kind: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · derivative.exercise_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · derivative.expiration_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document
June 26, 2023 Filed Jun 27, 2023 20:13 UTC	TriSalus Life Sciences, Inc. MTAC · Entity 5872	ConversionClass A Common Stock	6,249,999	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · nonDerivative · entry 1 MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner Dewey Christopher C · CIK 0001385015 · 10% owner MATLIN DAVID J · CIK 0001251956 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,249,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document
June 16, 2023 Filed Jun 20, 2023 11:57 UTC	Clene Inc. CLNN · Entity 7166	GrantWarrants (Right to buy) · Derivative	1,500,000	Not disclosed Strike: $1.10	Not disclosed	Disclosure SEC source: 0001562180-23-005321 · primarydocument.xml · derivative · entry 4 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires not disclosed F2 · price: The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. F4 · derivative.expiration_date: The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. Read SEC document
June 16, 2023 Filed Jun 20, 2023 11:57 UTC	Clene Inc. CLNN · Entity 7166	GrantWarrants (Right to buy) · Derivative	1,500,000	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001562180-23-005321 · primarydocument.xml · derivative · entry 3 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires not disclosed F2 · price: The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. F3 · derivative.expiration_date: The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. Read SEC document
June 16, 2023 Filed Jun 20, 2023 11:57 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	1,500,000	$0.80	$1,200,000.00	Disclosure SEC source: 0001562180-23-005321 · primarydocument.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,793,684 Read SEC document
May 04, 2023 Filed May 5, 2023 20:36 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	30,000	$0.00 Strike: $0.92	$0.00	Disclosure SEC source: 0001562180-23-003963 · primarydocument.xml · derivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-04 F2 · derivative.exercise_date: This option was granted on May 4, 2023 as an option for 30,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $0.92 per share. The options vest in 12 equal installments of Common Stock on the 4th day of each calendar month, beginning June 4, 2023, until such shares are fully vested. Read SEC document
May 04, 2023 Filed May 5, 2023 20:36 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	27,628	$0.00 Strike: $0.92	$0.00	Disclosure SEC source: 0001562180-23-003963 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,628 Underlying: Common Stock · 27,628 shares Expires 2033-05-04 F1 · derivative.exercise_date: This option was granted on May 4, 2023 as an option for 27,628 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $0.92 per share. The options vest immediately upon grant. Read SEC document
February 02, 2023 Filed Feb 3, 2023 21:01 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	15,894	$0.00 Strike: $1.62	$0.00	Disclosure SEC source: 0001562180-23-000898 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,894 Underlying: Common Stock · 15,894 shares Expires 2033-02-02 F1 · derivative.exercise_date: This option was granted on February 2, 2023 as an option for 15,894 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $1.62 per share. The options vest immediately upon grant. Read SEC document
November 03, 2022 Filed Nov 4, 2022 19:50 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	21,476	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0001562180-22-007507 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,476 Underlying: Common Stock · 21,476 shares Expires 2032-11-03 F1 · derivative.exercise_date: This option was granted on November 3, 2022 as an option for 21,476 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $1.19 per share. The options vest immediately upon grant. Read SEC document
November 02, 2022 Filed Nov 3, 2022 12:07 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	2,871,287	$1.01	$2,899,999.87	Disclosure SEC source: 0001562180-22-007458 · primarydocument.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,293,684 Read SEC document
August 04, 2022 Filed Aug 5, 2022 18:07 UTC	Clene Inc. CLNN · Entity 7166	GrantStock Options (Right to buy) · Derivative	6,717	$0.00 Strike: $3.79	$0.00	Disclosure SEC source: 0001562180-22-005904 · primarydocument.xml · derivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,717 Underlying: Common Stock · 6,717 shares Expires 2032-08-04 F1 · derivative.exercise_date: This option was granted on August 4, 2022 as an option for 6,717 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $3.79 per share. The options vest immediately upon grant. Read SEC document
June 17, 2022 Filed Jun 21, 2022 11:00 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	74,610	$2.51	$187,271.10	Disclosure SEC source: 0001562180-22-005217 · primarydocument.xml · nonDerivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,422,397 F2 · price: Mr. Matlin purchased 74,610 shares of common stock of Clene Inc. in multiple transactions on June 17, 2022 at prices ranging from $2.36 to $2.55, inclusive, for a weighted average price of $2.51 per share. Read SEC document
June 16, 2022 Filed Jun 21, 2022 11:00 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	75,000	$2.50	$187,500.00	Disclosure SEC source: 0001562180-22-005217 · primarydocument.xml · nonDerivative · entry 1 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,347,787 F1 · price: Mr. Matlin purchased 75,000 shares of common stock of Clene Inc. in multiple transactions on June 16, 2022 at prices ranging from $2.38 to $2.62, inclusive, for a weighted average price of $2.50 per share. Read SEC document
June 15, 2022 Filed Jun 16, 2022 11:13 UTC	Clene Inc. CLNN · Entity 7166	PurchaseCommon Stock	45,000	$2.66	$119,700.00	Disclosure SEC source: 0001562180-22-005128 · primarydocument.xml · nonDerivative · entry 2 MATLIN DAVID J · CIK 0001251956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272,787 F2 · price: Mr. Matlin purchased 45,000 shares of common stock of Clene Inc. in multiple transactions on June 15, 2022 at prices ranging from $2.53 to $2.73, inclusive, for a weighted average price of $2.66 per share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.